TY - JOUR
T1 - Exosomes as a drug delivery tool for cancer therapy
T2 - a new era for existing drugs and oncolytic viruses
AU - Kakiuchi, Yoshihiko
AU - Kuroda, Shinji
AU - Kanaya, Nobuhiko
AU - Kagawa, Shunsuke
AU - Tazawa, Hiroshi
AU - Fujiwara, Toshiyoshi
N1 - Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Introduction: Exosomes are cell-derived nanovesicles involved in cell-to-cell communications. These nanovesicles are generally considered to contain important carriers of information such as DNA and RNA, and show specific tropism. Areas covered: The combination of existing therapeutic agents with exosomes enhances therapeutic effects by increasing uptake into the tumor. Induction of immunogenic cell death (ICD) may also be triggered more strongly than with the drug alone. Oncolytic viruses (OVs) are even more effective as a drug in combination with exosomes. Although OVs are more likely to cause immune activity, combination with exosomes can exert synergistic effects. OVs have potent anti-tumor effects, but many limitations, such as being limited to local administration and vulnerability to attack by antibodies. Incorporation into exosomes can overcome these limitations and may allow effects against distant tumors. Expert opinion: Novel therapies using exosomes are very attractive in terms of enhancing therapeutic efficacy and reducing side effects. This approach also contains elements overcoming disadvantages in OVs, which have not been used clinically until now, and may usher in a new era of cancer treatments.
AB - Introduction: Exosomes are cell-derived nanovesicles involved in cell-to-cell communications. These nanovesicles are generally considered to contain important carriers of information such as DNA and RNA, and show specific tropism. Areas covered: The combination of existing therapeutic agents with exosomes enhances therapeutic effects by increasing uptake into the tumor. Induction of immunogenic cell death (ICD) may also be triggered more strongly than with the drug alone. Oncolytic viruses (OVs) are even more effective as a drug in combination with exosomes. Although OVs are more likely to cause immune activity, combination with exosomes can exert synergistic effects. OVs have potent anti-tumor effects, but many limitations, such as being limited to local administration and vulnerability to attack by antibodies. Incorporation into exosomes can overcome these limitations and may allow effects against distant tumors. Expert opinion: Novel therapies using exosomes are very attractive in terms of enhancing therapeutic efficacy and reducing side effects. This approach also contains elements overcoming disadvantages in OVs, which have not been used clinically until now, and may usher in a new era of cancer treatments.
KW - Cancer therapy
KW - chemotherapy
KW - drug delivery system
KW - exosome
KW - extracellular vesicle
KW - oncolytic virus
UR - http://www.scopus.com/inward/record.url?scp=85172019531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85172019531&partnerID=8YFLogxK
U2 - 10.1080/14728222.2023.2259102
DO - 10.1080/14728222.2023.2259102
M3 - Review article
C2 - 37742281
AN - SCOPUS:85172019531
SN - 1472-8222
VL - 27
SP - 807
EP - 816
JO - Expert Opinion on Therapeutic Targets
JF - Expert Opinion on Therapeutic Targets
IS - 9
ER -